Press Releases Elto PharmaAppoints Paula Trzepacz, MD

New Post Public Reply Private Reply Replies (0) Message Board
bms
612
Press Releases

Elto PharmaAppoints Paula Trzepacz, MD asChief Medical Advisor

Download as PDF
APRIL 30, 2018
Ex-Lilly Sr. Medical Fellow in Neurosciences to lead Parkinson's Phase 2b redesign
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) advancing Eltoprazine into a Phase 2b human clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced the appointment of Paula Trzepacz, MD to the role of Chief Medical Advisor. In this role, Dr. Trzepacz will focus on assisting in the redesign of the Elto Pharma Phase 2b PD-LID protocol, as well as assisting Elto Pharma's interim management team in raising the capital necessary to prepare for the re-initiation of the Eltoprazine Phase 2b PD-LID clinical program. Dr. Trzepacz brings with her nearly 20 years of clinical development experience in the neurosciences.

"I am excited to join Elto Pharma and assist in the preparation for the Phase 2b clinical development program in Parkinson's disease," said Dr. Trzepacz, newly appointed Chief Medical Advisor at Elto Pharma. "Eltoprazine has a robust safety package as a result of the extensive clinical research undertaken by Solvay (now Abbvie NYSE: ABBV), and has a compelling efficacy profile by virtue of the Phase 2a data published in the medical journal BRAIN in 2015 that clinically validated published pre-clinical data regarding the roles of the 5HT1a and 5HT1b receptors in PD-LID. Going forward, I will be working to complete the clinical development planning for Eltoprazine in PD-LID so that the program is in the best position possible to move rapidly into Phase 3 clinical development at the end of the planned Phase 2b. While I believe PD-LID is the appropriate lead indication for Eltoprazine by virtue of its orphan status, Eltoprazine also holds significant promise as a potential therapy in the areas of Agitation in Alzheimer's disease, as well as Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), both indications in which Eltoprazine has completed efficacy studies."

Prior to joining Elto Pharma, Dr. Trzepacz was the Chief Medical Officer at Neurotrope from June 2016 to September 2016, and has served as a member of Amarantus' Alzheimer's disease Diagnostics Scientific Advisory Board since 2015. Prior to Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she completed her tenure as Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years, Dr. Trzepacz was the medical lead for registration and regulatory related issues for its ADHD indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists, including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five-year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist. She is currently Volunteer Clinical Professor of Psychiatry at Indiana University School of Medicine where she has served since 2004. In the past Dr. Trzepacz was Associate Professor of Psychiatry and Neurology at the University of Pittsburgh School of Medicine and Professor of Psychiatry and Neurology at the University of Mississippi Medical School, where she directed clinical services and participated in NIH-funded research. She served as President of the American Neuropsychiatric Association from 2009 to 2011, and of the Academy of Psychosomatic Medicine in 2004-2005. Dr. Trzepacz serves on four journal editorial boards, most recently joining "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring." Dr. Trzepacz earned her B.A. at Wellesley College and M.D. at Geisel School of Medicine at Dartmouth College. After a year of Internal Medicine residency, she completed a Psychiatry residency and Consultation-Liaison Psychiatry Fellowship at Dartmouth.

"Dr. Trzepacz background and experience speaks for itself in clinical neuroscience research," said Gerald Commissiong, interim-CEO at Elto Pharma. "Elto Pharma is now focused on the redesign of the Phase 2b PD-LID study and raising capital in order to drive Elto Pharma forward."

About Elto Pharma, Inc.

Elto Pharma, Inc. is developing Eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile, with statistically significant efficacy results across multiple central nervous system indications. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID.

Eltoprazine was originally developed by Solvay (now Abbvie) in aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.

In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. for the purpose of raising capital to finance the further clinical development of Eltoprazine.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS), a JLABS alumnus company, is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF". MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also re-acquired rights to the Alzheimer's blood diagnostic LymPro Test , MSPrecise and NuroPro.

For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.

Amarantus Investor and Media Contact:

Howard Gostfrand

American Capital Ventures, Inc.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 107

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 73

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

Cathie Wood's Bold Investment in BitMine's Ethereum Strategy

Updated Category News Views 200

ARK Invest's Strategic Move ARK Invest, under the dynamic leadership of Cathie Wood, has taken a significant step by investing in BitMine Immersion Technologies Inc. The firm acquired nearly 4.8 million shares of BitMine, valued at an impressive $182 million through multiple ARK funds. Focus on Ethereum Acquisition This investment reflects BitMine's ambitious plan to...

Continue Reading
23andMe Advances Chapter 11 Plans with Court Approvals

Updated Category News Views 421

23andMe Secures Court Approval in Chapter 11 Process In a significant development, 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), recognized for its innovative approach in genetics and biotechnology, has received critical approvals from a Bankruptcy Court related to its Chapter 11 petitions. These petitions were filed, propelling the Company into a...

Continue Reading
Insights into Archer Aviation's Stock and Market Movements

Updated Category News Views 190

Understanding Archer Aviation's Stock Dynamics In a notable shift, investors with significant capital are displaying a bullish outlook on Archer Aviation. This uptrend is primarily highlighted by the option trading activities surrounding the company. Recent Option Trading Insights The latest data reveals that there have been 20 trades observed within Archer Aviation's...

Continue Reading
PACT Capital Partners Sets New Standards in Investment Strategies

Updated Category News Views 471

PACT Capital Partners Launches as an Independent Investment Firm PACT Capital LLC, known as PACT Capital Partners, has officially launched as a pioneering independent investment firm focused on empowering middle-market alternative asset managers. With significant backing from major players, the firm aims to carve a niche in the competitive investment landscape. Strategic...

Continue Reading
Bakery Mixes Forecast 2026-2036: Growth and Trends

Updated Category News Views 61

Standardization Taking Center Stage in Bakery Mixes Imagine a bustling bakery floor, with the smell of fresh bread wafting through the air. Yet behind the scenes lies a streamlined operation driven by pre-formulated mixes, which is exactly where the global bakery mixes market finds its muscle these days. Valued at $6.5 billion in 2025, the market has its sights set on...

Continue Reading